Zoetis Inc. (ZTS)

123.07
NYSE : Health Technology
Prev Close 126.64
Day Low/High 122.42 / 127.49
52 Wk Low/High 78.90 / 128.41
Avg Volume 1.95M
Exchange NYSE
Shares Outstanding 477.56M
Market Cap 60.48B
EPS 3.00
P/E Ratio 44.75
Div & Yield 0.66 (0.48%)

The Difference Between Europe and Us

Our market's been a terrific place to invest while Europe withers.

A View of Value Investing From Abroad

At a London conference, these two U.S. companies get some attention.

Kindred Bio CEO: Expect 3 Dynamic Dog Drugs by 2015

Kindred Bio CEO: Expect 3 Dynamic Dog Drugs by 2015

Kindred Biosciences stock has more than doubled since it started trading in December, but the company's employees are hard at work developing its osteoarthritis drug.

A Nutty Environment

Sometimes the facts just don't fit the story.

Zoetis downgraded at Morgan Stanley

Going Past the IPO Hype

These three companies can add balance to portfolios.

Get Your Portfolio Into the Bunker

Solid yielders like these should provide some much-needed cushion in the coming days.

Zoetis upgraded at Morgan Stanley

Steve Cohen's Best Ideas

Can't pick his brain? Look at his top five holdings instead.

Zoetis Zeroing In On China, Brazil

Zoetis Zeroing In On China, Brazil

Newly spun-off from Pfizer, Zoetis has big plans for its animal health business in the emerging markets, says the company's CEO Juan Ramon Alaix.

Zoetis upgraded at BofA/Merrill

Zoetis upgraded at BMO

Zoetis upgraded at BMO

Stock Picks for Pet Lovers

These name capitalize on the trend of spending on our pets, which has become recession proof.

Zoetis initiated at Neutral at Goldman

Zoetis rated new Neutral at BofA/Merrill

Zoetis rated new Underperform at BMO

Rules of the Game: Use Caution With IPOs

Investors should track companies with solid earnings growth, but avoid speculative ventures.

The Dow Flirts with 14,000

The Dow Flirts with 14,000

The January jobs report helps the Dow Jones Industrial Average cross 14,000.

Zoetis Gets IPO Makeover

Zoetis Gets IPO Makeover

Pfizer strips down Zoetis, but institutional buyers love it says IPO Desktop President Francis Gaskins.